From the Department of Brain Ischemia and Neurodegeneration, Institut d'Investigacions Biomèdiques de Barcelona (IIBB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain (X.d.l.R., C.J., A.M.P.); Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (A.C., C.J., Á.C., A.M.P.); ICFO-Institut de Ciències Fotòniques, Castelldefels, Spain (A.K.K., C.P.V., H.M.V., T.D.); and Functional Stroke Unit, Hospital Clínic, Barcelona, Spain (A.C., Á.C.).
Stroke. 2014 May;45(5):1453-9. doi: 10.1161/STROKEAHA.113.004111. Epub 2014 Mar 27.
Several lines of evidence support the involvement of mannose-binding lectin (MBL) in stroke brain damage. The lectin pathway of the complement system facilitates thrombin activation and clot formation under certain experimental conditions. In the present study, we examine whether MBL promotes thrombosis after ischemia/reperfusion and influences the course and prognosis of ischemic stroke.
Middle cerebral artery occlusion/reperfusion was performed in MBL-deficient (n=85) and wild-type (WT; n=83) mice, and the brain lesion was assessed by MRI at days 1 and 7. Relative cerebral blood flow was monitored up to 6 hours after middle cerebral artery occlusion with laser speckle contrast imaging. Fibrin(ogen) was analyzed in the brain vasculature and plasma, and the effects of thrombin inhibitor argatroban were evaluated to assess the role of MBL in thrombin activation.
Infarct volumes and neurological deficits were smaller in MBL knockout mice than in WT mice. Relative cerebral blood flow values during middle cerebral artery occlusion and at reperfusion were similar in both groups, but decreased during the next 6 hours in the WT group only. Also, the WT mice showed more fibrin(ogen) in brain vessels and a better outcome after argatroban treatment. In contrast, argatroban did not improve the outcome in MBL knockout mice.
MBL promotes brain damage and functional impairment after brain ischemia/reperfusion in mice. These effects are secondary to intravascular thrombosis and impaired relative cerebral blood flow during reperfusion. Argatroban protects WT mice, but not MBL knockout mice, emphasizing a role of MBL in local thrombus formation in acute ischemia/reperfusion.
有几条证据表明甘露糖结合凝集素(MBL)参与了脑卒中的脑损伤。补体系统的凝集素途径在某些实验条件下有助于凝血酶的激活和血栓形成。在本研究中,我们研究了 MBL 是否会促进缺血再灌注后的血栓形成,并影响缺血性脑卒中的病程和预后。
在 MBL 缺陷型(n=85)和野生型(WT;n=83)小鼠中进行大脑中动脉闭塞/再灌注,通过 MRI 在第 1 天和第 7 天评估脑损伤。通过激光散斑对比成像监测大脑中动脉闭塞后 6 小时内的相对脑血流。分析脑血管和血浆中的纤维蛋白(原),并评估凝血酶抑制剂 argatroban 的作用,以评估 MBL 在凝血酶激活中的作用。
与 WT 小鼠相比,MBL 敲除小鼠的梗死体积和神经功能缺损较小。两组的大脑中动脉闭塞和再灌注期间的相对脑血流值相似,但仅在 WT 组的下一个 6 小时内下降。此外,WT 小鼠的血管中含有更多的纤维蛋白(原),并且在 argatroban 治疗后预后更好。相比之下,argatroban 不能改善 MBL 敲除小鼠的预后。
MBL 促进了小鼠脑缺血再灌注后的脑损伤和功能障碍。这些作用继发于血管内血栓形成和再灌注期间相对脑血流受损。Argatroban 保护 WT 小鼠,但不保护 MBL 敲除小鼠,强调了 MBL 在急性缺血再灌注中局部血栓形成中的作用。